441 related articles for article (PubMed ID: 33147503)
1. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.
Prakash H; Upadhyay D; Bandapalli OR; Jain A; Kleuser B
Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106504. PubMed ID: 33147503
[TBL] [Abstract][Full Text] [Related]
2. Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection.
Pan Y; Gao F; Zhao S; Han J; Chen F
Clin Exp Pharmacol Physiol; 2021 May; 48(5):637-650. PubMed ID: 33565127
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipids as Modulators of SARS-CoV-2 Infection.
Törnquist K; Asghar MY; Srinivasan V; Korhonen L; Lindholm D
Front Cell Dev Biol; 2021; 9():689854. PubMed ID: 34222257
[TBL] [Abstract][Full Text] [Related]
4. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
McGowan EM; Haddadi N; Nassif NT; Lin Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.
Grau-Expósito J; Perea D; Suppi M; Massana N; Vergara A; Soler MJ; Trinite B; Blanco J; García-Pérez J; Alcamí J; Serrano-Mollar A; Rosado J; Falcó V; Genescà M; Buzon MJ
PLoS Pathog; 2022 Jan; 18(1):e1010171. PubMed ID: 35025963
[TBL] [Abstract][Full Text] [Related]
6. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
[No Abstract] [Full Text] [Related]
7. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
9. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
van de Leemput J; Han Z
Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
[TBL] [Abstract][Full Text] [Related]
10. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs.
Gupta A; Gupta GS
Mol Cell Biochem; 2021 Aug; 476(8):2917-2942. PubMed ID: 33745077
[TBL] [Abstract][Full Text] [Related]
11. Role of Multifunctional Cytoskeletal Filaments in
Norris V; Ovádi J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359986
[TBL] [Abstract][Full Text] [Related]
12. Recent Progress in the Development of Opaganib for the Treatment of Covid-19.
Smith CD; Maines LW; Keller SN; Katz Ben-Yair V; Fathi R; Plasse TF; Levitt ML
Drug Des Devel Ther; 2022; 16():2199-2211. PubMed ID: 35855741
[TBL] [Abstract][Full Text] [Related]
13. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
14. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
15. Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.
Vitner EB; Avraham R; Politi B; Melamed S; Israely T
Life Sci Alliance; 2022 Jan; 5(1):. PubMed ID: 34764206
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis.
Singh L; Bajaj S; Gadewar M; Verma N; Ansari MN; Saeedan AS; Kaithwas G; Singh M
Front Immunol; 2021; 12():660632. PubMed ID: 34305892
[TBL] [Abstract][Full Text] [Related]
17. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
18. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
19. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.
Lite C; Ahmed SSSJ; Juliet M; Freddy AJ
Pathog Dis; 2021 Feb; 79(2):. PubMed ID: 33469663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
